Follow RSS for latest reports on this topicOvarian Cancer - Market Research and Reports

Ovarian Cancer is cancer that starts in the female reproductive organs, the ovaries. It is the fifth most common cancer among women. 

Women at risk of Ovarian Cancer are those who have had few children (or had children at an older age), carriers of the BRCA1 or 2 genes, have a family history of the disease, some hormone replacement therapies. It is not thought to be increased by fertility drugs. One's risk may be decreased by regular pelvic examinations and removal of the ovaries in patient with BRCA mutations. The effectiveness of a screening program is currently being investigated.

Cases of ovarian cancer can be treated by surgery; total hysterectomy or bilateral salpingo-oophorectomy. Chemotherapy is used after surgery to treat any remaining disease.

About 76% of women with ovarian cancer survive 1 year after diagnosis, and about 45% live longer than 5 years after diagnosis. Early diagnosis is important.

Source; Adapted from NIH

BioPortfolio's Easy Ordering System

  1. Search for the report you need from our store
  2. Make online payment with our easy checkout process
  3. Receive PDF report via email

Easy Online Payment or Pro Forma Invoice

We accept the following credit cards...



or can supply a pro-forma invoice if required.

Related Reports:

We found over 40 reports that matched your search.

Next 40 Matches >

Refine your search, and find more matches, using the form above.

Oncology Drugs Market Global Report 2017 Including: Lung Cancer, Pancreatic Cancer, Breast Cancer, Prostate Cancer, Ovarian Cancer, Colorectal Cancer, Gastric Cancer, Non-Small Cell Lung Cancer , Kidney Cancer, Brain Tumor, Thyroid Cancer, Skin Cancer, Bladder Cancer, Cervical Cancer, Blood Cancer, Others (Kaposi Sarcoma, Aids-Related Lymphoma, Anal Cancer, Bone Cancer, Retinoblastoma, Testicula [Report Updated: 17-07-2017]

Oncology Drugs market covers drugs that are used in the treatment of a wide range of cancer, sarcoma, and tumor. Some of the bestselling oncology drugs in 2016 include Avastin, Herceptin, Revlimid, MabThera/Rituxan, Gleevac/Glivec, Alimta, Zytiga, Tasigna, Sandostatin, and Afinitor.


The global oncology drugs market was estimated to be around 8 billion as of 2016. The oncology drugs market market made up around 11% Read More >>>

Published:
2017-07-17

Published by: The Business Research Company

Prices Starting From:
$4000

Cancer Immunotherapy Market by Technology (Monoclonal Antibodies, Cytokines & Immunomodulators, and Others), by Application (Lung Cancer, Breast Cancer, Colorectal Cancer, Melanoma, Prostate Cancer, Head & Neck Cancer, and Others) by End User (Hospitals, Cancer Research Centers, and Clinics) - Global Opportunity Analysis and Industry Forecast, 2014-2022 [Report Updated: 18-05-2017]

CHAPTER 1 INTRODUCTION1.1. REPORT DESCRIPTION1.2. KEY BENEFITS1.3. KEY MARKET SEGMENT1.4. RESEARCH METHODOLOGY1.4.1. Secondary research1.4.2. Primary research1.5. ANALYST TOOLS AND MODELSCHAPTER 2 EXECUTIVE SUMMARY2.1. KEY FINDINGS OF THE STUDY2.2. CXO PERSPECTIVECHAPTER 3 MARKET OVERVIEW3.1. MARKET DEFINITION AND SCOPE3.2. KEY FINDINGS3.2.1. Top investment pockets3.2.2. Top winning strategies3.3....Read More >>>

Published:
2017-05-18

Published by: Allied Market Research

Prices Starting From:
$5370

Global Orphan Drugs Market by Disease Type (Oncologic Diseases, Metabolic Diseases, Hematologic and Immunologic Diseases, Infectious Diseases, Neurologic Diseases and Other Rare Diseases), Indication (Non-Hodgkin Lymphoma, Acute Myeloid Leukemia, Cystic Fibrosis, Glioma, Pancreatic Cancer, Ovarian Cancer, Multiple Myeloma, Duchenne Muscular Dystrophy, Graft vs Host Disease, Renal Cell Carcinoma an [Report Updated: 24-04-2017]

The pharmaceutical agents that are administered to treat, diagnose, and prevent life-threatening diseases (rare diseases) are known as orphan drugs. The global orphan drugs market accounted for 6 billion in 2015, and is anticipated to reach 9 billion by 2022, registering a CAGR of 6.8% from 2016 to 2022.nnOrphan drugs are used to treat rare (orphaned) diseases prevalent in a very small patie...Read More >>>

Published:
2017-04-24

Published by: Allied Market Research

Prices Starting From:
$5370

Cancer Biomarkers Market by Profiling Technology (Omic Technologies, Imaging Technologies, Immunoassays, and Cytogenetics Based Tests), Biomolecules (Genetic Biomarkers, Protein Biomarkers, and Glycoprotein Biomarkers), Cancer Type (Breast Cancer, Lung Cancer, Prostate Cancer, Colorectal Cancer, Stomach Cancer, and Other Cancers), Application (Diagnostics, Drug Discovery and Development, Prognosti [Report Updated: 01-12-2016]

Cancer biomarkers are biomolecules that specifies the existence of cancer or cancerous cells in the body. These are generally molecules that are released due to the presence of a tumor or a particular indication in the body to the presence of cancer. These molecules are densely distributed in tissues, urine, serum, blood, and other body fluids. Their expression levels serve as the basis or indicat...Read More >>>

Published:
2016-12-01

Published by: Allied Market Research

Prices Starting From:
$5370

Published:
2016-11-25

Published by: MarketsandMarkets

Prices Starting From:
$5650

Published:
2016-01-22

Published by: Industry ARC

Prices Starting From:
$5250

Additional Searches

You may also like to search separately for: Ovarian Cancer

We Stock...

{STICKYFOOTERMOBILE}